Document:

Converted by EDGARwiz

Exhibit 10.76

 STANDBY EQUITY DISTRIBUTION AGREEMENT

THIS AGREEMENT (“Agreement”), dated as of November 2, 2011 (the “
Execution Date”) is between GREYSTONE CAPITAL PARTNERS, a Nevada Corporation (the “Investor”), and BIOHEART, INC., a corporation organized and
existing under the laws of the State of Florida (the “Company”). 

WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company
shall issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to $3,000,000 of the Company’s common stock, par value $0.001 per
share (the “Common Stock”); and

 WHEREAS, such offers and sales of the Common Stock by the Company, in exchange for the Commitment
Amount will be made subsequent to the Effective Date (hereinafter defined) and otherwise will be made in reliance upon the provisions of Regulation D (“Regulation D”) of the
Securities Act of 1933, as amended, and the regulations promulgated thereunder (the “Securities Act”), and or upon such other exemption from the registration requirements of
the Securities Act as may be available with respect to any or all of the investments to be made hereunder; and 

WHEREAS, any resales of the Common Stock by the Investor will be made solely pursuant to the Registration
Statement. 

NOW, THEREFORE, the parties hereto agree as follows:

Article I. Certain Definitions

Section 1.01

“Advance” shall mean the portion of the Commitment Amount
(hereinafter defined) requested by the Company in an Advance Notice.

Section 1.02

“Advance Date” shall mean the third (3rd)
Trading Day (hereinafter defined) after the applicable Advance Notice Date (hereinafter defined) for each Advance.

Section 1.03

“Advance Notice” shall mean a written notice in the form of
Exhibit A attached hereto to the Investor executed by an officer of the Company and setting forth the Advance amount that the Company requests from the Investor.

Section 1.04

“Advance Notice Date” shall mean each date the Company
delivers (in accordance with of this Agreement) to the Investor an Advance Notice requiring the Investor to purchase shares of Common Stock from the Company subject to the terms of this
Agreement. No Advance Notice Date shall be less than five (5) Trading Days after the prior Advance Notice Date.

Section 1.05

“Closing” shall mean any one of the closings of a purchase
and sale of the Common Stock wherein the sale of Common Stock and the payment of the relevant Purchase Price (hereinafter defined) is completed pursuant to this Agreement. 

Section 1.06

“Commitment Amount” shall mean the aggregate amount of up
to $3,000,000 which the Investor has agreed to provide to the Company in exchange for the purchase by the Investor of the Common Stock pursuant to the terms and conditions of this Agreement.

 

Section 1.07

“Commitment Period” shall mean the period commencing on the
Effective Date, and expiring upon the termination of this Agreement in accordance with Section 10.02 hereof.

Section 1.08

“Common Stock” shall have the meaning set forth in the
recitals of this Agreement. 

Section 1.09

“Damages” shall mean any loss, claim, damage, liability,
costs and expenses (including, without limitation, reasonable attorney’s fees and disbursements and costs and expenses of expert witnesses and investigation).

Section 1.10

“Effective Date” shall mean the date on which the SEC first
declares effective the Registration Statement.

Section 1.11

“Exchange Act” shall mean the Securities Exchange Act of
1934, as amended, and the rules and regulations promulgated thereunder.

Section 1.12

“Investor’s Shares” shall have the meaning set forth
in Section 12.04(b) of this Agreement.

Section 1.13

“Material Adverse Effect” shall mean any condition,
circumstance, or situation that may result in, or reasonably be expected to result in (i) a material adverse effect on the legality, validity or enforceability of this Agreement or the transactions
contemplated herein, (ii) a material adverse effect on the results of operations, assets, business or condition (financial or otherwise) of the Company, taken as a whole, or (iii) a material adverse
effect on the Company’s ability to perform in any material respect on a timely basis its obligations under this Agreement.

Section 1.14

“Market Price” shall mean the lowest daily VWAP of the
Common Stock during a Pricing Period. 

Section 1.15

“Maximum Advance Amount” shall be, for each Advance Notice,
an amount equal to the product of (i) the Market Price, and (ii) a number of shares of the Common Stock equal to fifty percent (50%) of the average Weekly Volume (hereinafter defined) during the ten
(10) consecutive Trading Days immediately prior to an Advance Notice Date.

Section 1.16

[reserved]

Section 1.17

“Person” shall mean an individual, a corporation, a
partnership, an association, a trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.

Section 1.18

“Pricing Period” shall mean the five (5) consecutive
Trading Days immediately preceding an Advance Notice Date.

Section 1.19

“Principal Market” shall mean the Nasdaq Global Select
Market, the Nasdaq Global Market, the Nasdaq Capital Market, the American Stock Exchange, the OTC Bulletin Board or the New York Stock Exchange, whichever is at the time the principal trading
exchange or market for the Common Stock.

Section 1.20

“Purchase Price” shall be equal to eighty percent (80%) of
the Market Price during the relevant Pricing Period.

Section 1.21

 “Registrable Securities” shall mean the Shares to be
issued hereunder (i) in respect of which the Registration Statement has not been declared effective by the SEC, (ii) which have not been sold under circumstances meeting all of the applicable
conditions of Rule 144 (or any similar provision then in force) under the Securities Act (“Rule 144”) or (iii) which have not been otherwise transferred to a holder who may
trade such shares without restriction under the Securities Act, and the Company has delivered a new certificate or other evidence of ownership for such securities not bearing a restrictive legend.
 

Section 1.22

“Registration Rights Agreement” shall mean the Registration
Rights Agreement dated the date hereof, regarding the filing of the Registration Statement for the resale of the Registrable Securities, entered into between the Company and the Investor.

Section 1.23

“Registration Statement” shall mean a registration
statement on Form S-1 or on such other form promulgated by the SEC for which the Company then qualifies and which counsel for the Company shall deem appropriate, and which form shall be available for
the resale of the Registrable Securities to be registered thereunder in accordance with the provisions of this Agreement and the Registration Rights Agreement, and in accordance with the intended
method of distribution of such securities), for the registration of the resale by the Investor of the Registrable Securities under the Securities Act.

Section 1.24

“Regulation D” shall have the meaning set forth in the
recitals of this Agreement.

Section 1.25

“SEC” means the United States Securities & Exchange
Commission.

Section 1.26

“Securities Act” shall have the meaning set forth in the
recitals of this Agreement.

Section 1.27

“Shares” shall mean the Investor’s Shares and the
shares of the Common Stock to be issued to the Investor by the Company from time to time hereunder pursuant to Advances.   

Section 1.28

“Trading Day” shall mean any day during which the New York
Stock Exchange shall be open for business.

Section 1.29

“VWAP” means, as of any date, the daily dollar
volume-weighted average price for such security on such date as reported by Bloomberg, LP through its “Historical Price Table Screen (HP)” with Market: Weighted Ave function selected, or,
if no dollar volume-weighted average price is reported for such security on such date, then the average of the highest closing bid price and the lowest closing ask price of any of the market makers
for such security on such date.

Section 1.30

“Weekly Volume” means the shares of the Company’s
common stock traded on the Principal Market during the period of five (5) consecutive trading days immediately prior to an Advance Notice Date.

Article II. Advances

Section 2.01

Advances. Subject to the terms and conditions of this Agreement, the
Company, at its sole and exclusive option may, by the delivery in the Company’s sole discretion of Advance Notices, issue and sell to the Investor and the Investor shall purchase from the
Company, shares of the Common Stock. 

 

Section 2.02

Mechanics.

(a)

Advance Notice. At any time and from time to time during the
Commitment Period, the Company may, subject to the conditions set forth in this Agreement, require the Investor to purchase shares of Common Stock by delivering an Advance Notice to the Investor;
provided however, that (i) the amount for each Advance as designated by the Company in the applicable Advance Notice shall not be more than the Maximum Advance Amount, and (ii) the aggregate amount
of the Advances pursuant to this Agreement shall not exceed the Commitment Amount. The Company acknowledges that the Investor may sell shares of the Company’s Common Stock corresponding
with a particular Advance Notice after the Advance Notice is received by the Investor. No Advance Notice Date shall be less than five (5) Trading Days after the delivery date of the prior
Advance Notice Date.

(b)

Date of Delivery of Advance Notice. Advance Notices shall be
delivered in accordance with the instructions set forth on the bottom of Exhibit A. An Advance Notice shall be deemed delivered on (i) the Trading Day it is received by facsimile, email or
otherwise by the Investor if such notice is received prior to 5:00 pm Eastern Time, or (ii) the immediately succeeding Trading Day if it is received by facsimile email or otherwise after 5:00 pm
Eastern Time on a Trading Day or at any time on a day which is not a Trading Day. No Advance Notice may be deemed delivered on a day that is not a Trading Day. 

Section 2.03

Closings. Each Closing shall take place on each applicable
Advance Date in accordance with the procedures set forth below.  In connection with each Closing the Company and the Investor shall fulfill each of its obligations as set forth below: 

(a)

Prior to two o’clock pm, EST (1400 hours) on each Advance Date, the
Investor shall deliver to the Company a written document (each a “Settlement Document”) setting forth the amount of the Advance (taking into account any adjustments pursuant
thereto), the Purchase Price, the number of shares of the Common Stock to be issued and subscribed for, and a report by Bloomberg, LP indicating the VWAP for each of the Trading Days during the
relevant Pricing Period, in each case taking into account the terms and conditions of this Agreement.

(b)

Upon receipt of the Settlement Document with respect to each Advance, the
Company shall (i) immediately review and either approve such Settlement Document or provide any corrections to the Settlement Document (a “Corrected Settlement Document”) and
return it to the Investor on such Advance Date, and (ii) along with the return of each Settlement Document or Corrected Settlement Document confirm that it has all the legal rights and power
necessary for the issuance of the shares of the Common Stock applicable to such Advance and that the sale and issuance of such shares of the Common Stock shall be legally permitted by all laws and
regulations to which the Company is subject or that the Company shall have the availability of exemptions therefrom. 

(c)

Upon receipt of any Corrected Settlement Document pursuant to the above, the
Investor shall immediately review and either approve such Corrected Settlement Document or if the Investor feels additional corrections are necessary, such Corrected Settlement Document will be
promptly submitted to an independent, reputable appraiser jointly selected by the Company and the Investor. Such appraiser will review and if necessary, revise, such Corrected Settlement
Document. The determination of such appraiser shall be deemed binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne equally by both parties.

(d)

Immediately after a Settlement Document or Corrected Settlement Document with
respect to an Advance is deemed final, (i) the Company shall deliver to the Investor such number of shares of the Common Stock registered in the name of the Investor as shall equal (x) the amount of
the Advance, divided by (y) the Purchase Price (as each of (x) and (y) are specified in such Settlement Document or Corrected Settlement Document), and (ii) upon receipt of such shares, the Investor
shall

 

deliver to the Company the amount of the Advance specified in such Settlement
Document or Corrected Settlement Document by wire transfer of immediately available funds. The certificates
evidencing such shares of the Common Stock delivered pursuant hereto shall be free of restrictive legends. If so indicated in the Settlement Document or Corrected Document, such shares of the
Common stock shall be delivered by the Company’s transfer agent via DWAC to the Investor’s account. 

(e)

On or prior to the Advance Date, each of the Company and the Investor shall
deliver to the other all documents, instruments and writings required to be delivered by either of them pursuant to this Agreement in order to implement and effect the transactions contemplated
herein. 

(f)

Each of the Company and the Investor acknowledge and agree that with respect to
each Settlement Document that “time is of the essence” with respect to a Closing occurring on, or as close as possible to the, the relevant Advance Date, and with respect to each Corrected
Settlement Document that “time is of the essence” with respect to a Closing occurring immediately after either (i) approval of such Corrected Settlement Document by the Investor, or (ii)
receipt by the parties of the appraiser’s determination.

Section 2.04

Hardship; Penalties. In the event the Investor sells shares of
the Company’s common stock after receipt of an Advance Notice and the Company fails to deliver to the Investor at the Closing the shares of the Common Stock corresponding to the applicable
Settlement Document or Corrected Settlement Document pursuant to Section 2.03, the Company acknowledges that the Investor shall suffer financial hardship and therefore shall be liable for any and all
losses, commissions, fees, or financial hardship caused to the Investor. If the Company does not issue to the Investor when due the shares of the Common Stock corresponding to the applicable
Settlement Document or Corrected Settlement Document pursuant to Section 2.03, then the Company will pay the Investor as liquidated damages, as its sole remedy in such event, the sum of two hundred
and no/100 dollars ($200.00) for each ten thousand and no/100 dollars ($10,000.00) or portion thereof of such Advance for each of the first five (5) calendar days, and four hundred and no/100 dollars
($400.00) for each calendar day thereafter that such shares of the Common Stock remain unissued.

Article III. Representations and Warranties of Investor

Investor hereby represents and warrants to, and agrees with, the Company that the following are true and correct as
of the date hereof and will be true and correct as of each Advance Date:

Section 3.01

Organization and Authorization. The Investor is duly
incorporated or organized and validly existing in the jurisdiction of its incorporation or organization and has all requisite power and authority to purchase and hold the Shares. The decision
to invest and the execution and delivery of this Agreement by the Investor, the performance by the Investor of its obligations hereunder and the consummation by the Investor of the transactions
contemplated hereby have been duly authorized by the Investor and requires no other proceedings on the part of the Investor. The Investor has the right, power and authority to execute and
deliver this Agreement and all other instruments (including, without limitation, the Registration Rights Agreement), on behalf of the Investor. This Agreement has been duly executed and
delivered by the Investor and, assuming the execution and delivery hereof and acceptance thereof by the Company, will constitute the legal, valid and binding obligations of the Investor, enforceable
against the Investor in accordance with its terms.

Section 3.02

Evaluation of Risks. The Investor has such knowledge and
experience in financial, tax and business matters as to be capable of evaluating the merits and risks of, and bearing the economic risks entailed by, an investment in the Company and of protecting
its interests in connection with this transaction. It recognizes that its investment in the Company involves a high degree of risk.

 

Section 3.03

No Legal Advice From the Company. The Investor acknowledges
that it had the opportunity to review this Agreement and the transactions contemplated by this Agreement with its own legal counsel and investment and tax advisors. The Investor is relying
solely on such counsel and advisors and not on any statements or representations of the Company or any of its representatives or agents for legal, tax or investment advice with respect to this
investment, the transactions contemplated by this Agreement or the securities laws of any jurisdiction.

Section 3.04

Investment Purpose. The Shares are being purchased by the Investor
for its own account, and for investment purposes. The Investor agrees not to assign or in any way transfer the Investor’s rights to the Shares or any interest therein and acknowledges that
the Company will not recognize any purported assignment or transfer except in accordance with applicable Federal and state securities laws. No other Person has or will have a direct or indirect
beneficial interest in the Shares. The Investor agrees not to sell, hypothecate or otherwise transfer the Shares unless the Shares are registered under Federal and applicable state securities
laws or unless, in the opinion of counsel satisfactory to the Company, an exemption from such registration requirement is available.

Section 3.05

Accredited Investor. The Investor is an “Accredited
Investor” as that term is defined in Rule 501(a)(3) of Regulation D of the Securities Act.

Section 3.06

Information. The Investor and its advisors (and its counsel),
if any, have been furnished with all materials relating to the business, finances and operations of the Company and information it deemed material to making an informed investment decision. The
Investor and its advisors, if any, have been afforded the opportunity to ask questions of the Company and its management. Neither such inquiries nor any other due diligence investigations
conducted by the Investor or its advisors, if any, or its representatives shall modify, amend or affect the Investor’s right to rely on the Company’s representations and warranties
contained in this Agreement. The Investor understands that its investment involves a high degree of risk. The Investor is in a position regarding the Company, which, based upon
employment, family relationship or economic bargaining power, enabled and enables such Investor to obtain information from the Company in order to evaluate the merits and risks of this investment.
The Investor has sought such accounting, legal and tax advice, as it has considered necessary to make an informed investment decision with respect to the transactions contemplated by this Agreement.

Section 3.07

Receipt of Documents. The Investor and its counsel have received and
read in their entirety: (i) this Agreement and Exhibit A annexed hereto; (ii) all due diligence and other information necessary to verify the accuracy and completeness of the representations,
warranties and covenants of the Company contained in this Agreement; (iii) the Company’s reports on Form 10-K for the year ended December 31, 2010 and on Form 10-Q for the periods ended March
31, 2011, and June 30, 2011; and (iv) answers to all questions the Investor submitted to the Company regarding the Company; and the Investor has relied on the information contained therein and
on its own due diligence investigation and has not been furnished any other documents, literature, memorandum or prospectus. 

Section 3.08

No General Solicitation. Neither the Company, nor any of its
affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in
connection with the offer or sale of the Shares.

Section 3.09

Not an Affiliate. The Investor is not an officer, director or a
Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with the Company or any “Affiliate” (as that
term is defined in Rule 405 of the Securities Act) of the Company. 

 

Section 3.10

Trading Activities. The Investor’s trading activities with respect to the Company’s common stock is and shall be in compliance with all applicable federal and state securities laws, rules and
regulations and the rules and regulations of the Principal Market on which the Company’s common stock is listed or traded.

Article IV. Representations and Warranties of the Company

Except as stated below or in the SEC Documents (as defined herein), the Company hereby represents and warrants to,
and agrees with, the Investor that the following are true and correct as of the date hereof and will be true and correct as of each Advance Date:

Section 4.01

Organization and Qualification. The Company is duly
incorporated and validly existing in the jurisdiction of its incorporation and has all requisite corporate power to own its properties and to carry on its business as now being conducted. Each
of the Company and its subsidiary is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it makes
such qualification necessary, except to the extent that the failure to be so qualified or to be in good standing would not have a Material Adverse Effect on the Company and its subsidiary taken as a
whole.

Section 4.02

Authorization, Enforcement, Compliance with Other Instruments.
 (i) The Company has the requisite corporate power and authority to enter into and perform this Agreement, the Registration Rights Agreement and any related agreements, in accordance with the
terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Registration Rights Agreement and any related agreements by the Company and the consummation by it of the transactions
contemplated hereby and thereby, have been duly authorized by the Company’s Board of Directors and no further consent or authorization is required by the Company, its Board of Directors or its
stockholders, (iii) this Agreement, the Registration Rights Agreement and any related agreements have been duly executed and delivered by the Company, (iv) this Agreement, the Registration
Rights Agreement and assuming the execution and delivery thereof and acceptance by the Investor constitute together with any related agreements the valid and binding obligations of the Company
enforceable against the Company in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

Section 4.03

Capitalization. The authorized capital stock of the Company
consists of 195,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”), of which 81,791,338 shares of Common
Stock and zero shares of Preferred Stock are issued and outstanding as of the Execution Date. All of such outstanding shares have been validly issued and are fully paid and nonassessable.
 Except as disclosed in the SEC Documents, no shares of Common Stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the
Company. Except as disclosed in the SEC Documents, or in the capitalization table attached hereto as Exhibit B, and made a part hereof, as of the date hereof, (i) there are no
outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of
the Company or its subsidiary, or contracts, commitments, understandings or arrangements by which the Company or its subsidiary is or may become bound to issue additional shares of capital stock of
the Company or its subsidiary or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares
of capital stock of the Company or its subsidiary, (ii) there are no outstanding debt securities (iii) there are no outstanding registration statements other than on Form S-8, and (iv)
there are no agreements or arrangements under which the Company or its subsidiary is obligated to include in the Registration Statement any of their securities 

 

(except pursuant to the Registration
Rights Agreement). There are no securities or instruments containing anti-dilution or
similar provisions that will be triggered by this Agreement or any related agreement or the consummation of the transactions described herein or therein. The Company has furnished to the Investor
true and correct copies of the Company’s Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate of Incorporation”), and the
Company’s By-laws, as in effect on the date hereof (the “By-laws”), and the terms of all securities convertible into or exercisable for Common Stock and the material
rights of the holders thereof in respect thereto.

Section 4.04

No Conflict. The execution, delivery and performance of this
Agreement by the Company and the consummation by the Company of the transactions contemplated hereby will not (i) result in a violation of the Certificate of Incorporation, any certificate of
designation of any outstanding series of preferred stock of the Company or the By-laws or (ii) conflict with or constitute a default (or an event which with notice or lapse of time or both would
become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or its subsidiary is a
party, or result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules and regulations of the Principal
Market on which the Common Stock is quoted) applicable to the Company or its subsidiary or by which any material property or asset of the Company or its subsidiary is bound or affected and which
would cause a Material Adverse Effect. Except as disclosed in the SEC Documents, neither the Company nor its subsidiary is in violation of any term of or in default under its Articles of
Incorporation or By-laws, or any material contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or
its subsidiary. The business of the Company and its subsidiary is not being conducted in violation of any material law, ordinance, regulation of any governmental entity. Except as
specifically contemplated by this Agreement and as required under the Securities Act and any applicable state securities laws, the Company is not required to obtain any consent, authorization or
order of, or make any filing or registration with, any court or governmental agency in order
for it to execute, deliver or perform any of its obligations under or as contemplated by this Agreement or the Registration Rights Agreement in accordance with the terms hereof or thereof. All
consents, authorizations, orders, filings and registrations, other than the filing of the Registration Statement, which the Company is required to obtain pursuant to the preceding sentence have been
obtained or effected on or prior to the date hereof. The Company and its subsidiary are unaware of any fact or circumstance which might give rise to any of the foregoing.

Section 4.05

SEC Documents; Financial Statements. The Company has filed all
reports, schedules, forms, statements and other documents required to be filed by it with the SEC under the Securities Exchange Act for the two years preceding the date hereof (or such shorter period
as the Company was required by law or regulation to file such material) (all of the foregoing filed prior to the date hereof or amended after the date hereof and all exhibits included therein and
financial statements and schedules thereto and documents incorporated by reference therein, being hereinafter referred to as the “SEC Documents”) on timely basis or has
received a valid extension of such time of filing and has filed any such SEC Document prior to the expiration of any such extension. The Company has delivered to the Investor or its
representative, or made available through the SEC’s website at http://www.sec.gov, true and complete copies of the SEC Documents. As of their respective dates, the SEC Documents complied in all
material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time
they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied as to
form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements have been prepared in
accordance with generally accepted

 

accounting principles in the United
States of America (“GAAP”), consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto, or
(ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit
adjustments). No other information provided by or on behalf of the Company to the Investor which is not included in the SEC Documents contains any untrue statement of a material fact or omits
to state any material fact necessary in order to make the statements therein, in the light of the circumstance under which they are or were made, not misleading.

Section 4.06

10b-5. The SEC Documents do not include any untrue statements
of material fact, nor do they omit to state any material fact required to be stated therein necessary to make the statements made, in light of the circumstances under which they were made, not
misleading.

Section 4.07

No Default. Except as disclosed in the SEC Documents, the
Company is not in default in the performance or observance of any material obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust or other material
instrument or agreement to which it is a party or by which it or its property is bound and neither the execution, nor the delivery by the Company, nor the performance by the Company of its
obligations under this Agreement or any of the exhibits or attachments hereto will conflict with or result in the breach or violation of any of the terms or provisions of, or constitute a default or
result in the creation or imposition of any lien or charge on any assets or properties of the Company under its Certificate of Incorporation, By-Laws, any material indenture, mortgage, deed of trust
or other material agreement applicable to the Company or instrument to which the Company is a party or by which it is bound, or any statute, or any decree, judgment, order, rule or regulation of any
court, governmental agency or body having jurisdiction over the Company or its properties, in each case which default, lien or charge is likely to cause a Material Adverse Effect.

Section 4.08

Intellectual Property Rights. The Company and its subsidiary
own or possess adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions,
licenses, approvals, governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted.  The Company and its subsidiary do not have
any knowledge of any infringement by the Company or its subsidiary of trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service
mark registrations, trade secret or other similar rights of others, and, to the knowledge of the Company, there is no claim, action or proceeding being made or brought against, or to the
Company’s knowledge, being threatened against, the Company or its subsidiary regarding trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks,
service mark registrations, trade secret or other infringement; and the Company and its subsidiary are unaware of any fact or circumstance which might give rise to any of the foregoing. 

Section 4.09

Employee Relations. Neither the Company nor its subsidiary is
involved in any labor dispute nor, to the knowledge of the Company or its subsidiary, is any such dispute threatened. None of the Company’s or its subsidiary’s employees is a member
of a union and the Company and its subsidiary believe that their relations with their employees are good.

Section 4.10

Environmental Laws. The Company and its subsidiary are (i) in
compliance with any and all applicable material foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or other approvals 

 

required of them under applicable
Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval.

Section 4.11

Title. Except as set forth in the SEC Documents, the Company
has good and marketable title to its properties and material assets owned by it, free and clear of any pledge, lien, security interest, encumbrance, claim or equitable interest other than such as are
not material to the business of the Company. Except as set forth in the SEC Documents, any real property and facilities held under lease by the Company or its subsidiary are held by them under
valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its
subsidiary.

Section 4.12

Insurance. The Company and its subsidiary are insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the
Company and its subsidiary are engaged. Neither the Company nor its subsidiary has been refused any insurance coverage sought or applied for and neither the Company nor its subsidiary has any
reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at a cost that would not have a Material Adverse
Effect from similar insurers as may be necessary to continue its business.

Section 4.13

Regulatory Permits. The Company and its subsidiary possess all
material certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company
nor its subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit.

Section 4.14

Internal Accounting Controls. The Company and its subsidiary
maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is
permitted only in accordance with management’s general or specific authorization and (iv) the recorded amounts for assets is compared with the value of such assets at reasonable intervals and
appropriate action is taken with respect to any differences.

Section 4.15

No Material Adverse Breaches. Except as set forth in the SEC
Documents, neither the Company nor its subsidiary is subject to any charter, corporate or other legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the
Company’s officers has or is expected in the future to have a Material Adverse Effect on the business, properties, operations, financial condition, results of operations or prospects of the
Company or its subsidiaries. Except as set forth in the SEC Documents, neither the Company nor its subsidiary is in breach of any contract or agreement which breach, in the judgment of the
Company’s officers, has or is expected to have a Material Adverse Effect on the business, properties, operations, financial condition, results of operations or prospects of the Company or its
subsidiary.

Section 4.16

Absence of Litigation. Except as set forth in the SEC
Documents, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending against or affecting
the Company, the Common Stock or the Company’s subsidiary, wherein an unfavorable decision, ruling or finding would (i) have a Material Adverse Effect on the transactions contemplated hereby
(ii) adversely affect the validity or enforceability of, or the authority or ability of the Company to perform its obligations under, this Agreement or any of the documents contemplated herein, or
(iii) except as expressly disclosed in the SEC Documents, have a Material Adverse Effect.

 

Section 4.17

Subsidiaries. Except as disclosed in the SEC Documents, the
Company does not presently own or control, directly or indirectly, any interest in any other corporation, partnership, association or other business entity.

Section 4.18

Tax Status. Except as disclosed in the SEC Documents, the
Company and its subsidiary has made or filed all federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject and (unless and only
to the extent that the Company and its subsidiary has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) has paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside
on its books provision reasonably adequate for the payment of all taxes for the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim

Section 4.19

Certain Transactions. Except as set forth in the SEC Documents
none of the officers, directors, or employees of the Company is presently a party to any transaction with the Company (other than for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from
any officer, director or such employee or, to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee or partner.

Section 4.20

Fees and Rights of First Refusal. The Company is not obligated
to offer the Shares on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or former shareholders of the Company, underwriters, brokers, agents or
other third parties.

Section 4.21

Use of Proceeds. The Company shall use the net proceeds from
the sale of the Shares for working capital and other general corporate purposes.

Section 4.22

Further Representation and Warranties of the Company. For as
long as any of the Shares are owned by the Investor, the Company acknowledges, represents, warrants and agrees that it will use its best efforts to maintain the listing of its Common Stock on a
Principal Market.

Section 4.23

Opinion of Counsel at Closing. Investor shall receive, on the
date hereof, an opinion letter from counsel to the Company in regards to this transaction, in an agreed upon form. 

Section 4.24

Dilution. The Company is aware and acknowledges that issuance
of the Shares could cause dilution to existing shareholders and could significantly increase the outstanding number of shares of Common Stock. 

Section 4.25

Acknowledgment Regarding Investor’s Purchase of Shares. The
Company acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated
hereunder and any advice given by the Investor or any of its representatives or agents in connection with this Agreement and the transactions contemplated hereunder is merely incidental to the
Investor’s purchase of the Shares. The Company is aware and acknowledges that it may not be able to request Advances under this Agreement if it cannot obtain an effective Registration
Statement or if issuances of Common Stock pursuant to any Advances would violate any rules of the Principal Market. The Company further is aware 

 

and acknowledges that the Investor’s Shares
and any fees paid pursuant to this Agreement shall be earned on the date hereof and not refundable or returnable under any circumstances.

Article V.  Indemnification

The Investor and the Company represent to the other the following with respect to itself:

Section 5.01

Indemnification.

(a)

 In consideration of the Investor’s execution and delivery of this
Agreement, and in addition to all of the Company’s other obligations under this Agreement, the Company shall defend, protect, indemnify and hold harmless the Investor, and all of its officers,
directors, partners, employees and agents (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Investor
Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith
(irrespective of whether any such Investor Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the
“Indemnified Liabilities”), incurred by the Investor Indemnitees or any of them as a result of, or arising out of, or relating to (i) any misrepresentation or breach of any
representation or warranty made by the Company in this Agreement or the Registration Rights Agreement or any other certificate, instrument or document contemplated hereby or thereby, (ii any breach
of any covenant, agreement or obligation of the Company contained in this Agreement or the Registration Rights Agreement or any other certificate, instrument or document contemplated hereby or
thereby, or (iii) any cause of action, suit or claim brought or made against such Investor Indemnitee not arising out of any action or inaction of an Investor Indemnitee, and arising out of or
resulting from the execution, delivery, performance or enforcement of this Agreement or any other instrument, document or agreement executed pursuant hereto by any of the Investor Indemnitees.
 To the extent that the foregoing undertaking by the Company may be unenforceable for
any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible under applicable law.

(b)

 In consideration of the Company’s execution and delivery of this
Agreement, and in addition to all of the Investor’s other obligations under this Agreement, the Investor shall defend, protect, indemnify and hold harmless the Company and all of its officers,
directors, shareholders, employees and agents (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Company
Indemnitees”) from and against any and all Indemnified Liabilities incurred by the Company Indemnitees or any of them as a result of, or arising out of, or relating to (i) any
misrepresentation or breach of any representation or warranty made by the Investor in this Agreement, the Registration Rights Agreement, or any instrument or document contemplated hereby or thereby
executed by the Investor, (ii) any breach of any covenant, agreement or obligation of the Investor(s) contained in this Agreement, the Registration Rights Agreement or any other certificate,
instrument or document contemplated hereby or thereby executed by the Investor, or (iii) any cause of action, suit or claim brought or made against such Company Indemnitee based on
 misrepresentations or due to a breach by the Investor and arising out of or resulting from the execution, delivery, performance or enforcement of this Agreement or any other instrument,
document or agreement executed pursuant hereto by any of the Company Indemnitees. To the extent that the foregoing undertaking by the Investor may be unenforceable for any reason, the Investor
shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities, which is permissible under applicable law.

(c)

The

obligations
 of the parties under this Section 5.01 to indemnify or make contributions

to the payment and satisfaction of each of the Indemnified Liabilities
 shall survive the termination of this Agreement.

 

Article VI. 

Covenants of the Company

Section 6.01

Registration Rights. The Company shall use its best efforts to
cause the Registration Rights Agreement to remain in full force and effect and the Company shall comply in all material respects with the terms thereof.

Section 6.02

Listing of Common Stock. The Company shall use its best efforts
to at all times maintain the Common Stock’s authorization for quotation or listing on a Principal Market. 

Section 6.03

Exchange Act Registration. The Company will use its best
efforts to cause its Common Stock to continue to be registered under Section 12(g) of the Exchange Act, will file in a timely manner all reports and other documents required of it as a reporting
company under the Exchange Act and will not take any action or file any document (whether or not permitted by Exchange Act or the rules thereunder) to terminate or suspend such registration or to
terminate or suspend its reporting and filing obligations under said Exchange Act.

Section 6.04

Transfer Agent Instructions. On the Effective Date the Company
shall deliver instructions to its transfer agent to issue shares of the Common Stock to the Investor free of restrictive legends on or before the date of each Closing.

Section 6.05

Corporate Existence. The Company will take all steps necessary
to preserve and continue the corporate existence of the Company.

Section 6.06

Notice of Certain Events Affecting Registration; Suspension of Right to
Request an Advance. The Company will immediately notify the Investor upon its becoming aware of the occurrence of any of the following events in respect of the Registration Statement or
related prospectus relating to an offering of Registrable Securities: (i) receipt from the SEC or any other Federal or state governmental authority during the period of effectiveness of the
Registration Statement of any request for additional information or for amendments or supplements to the registration statement or related prospectus; (ii) the issuance by the SEC or any other
Federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt of any
notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction or the initiation or threatening of
any proceeding for such purpose; (iv) the happening of any event that makes any statement made in the Registration Statement or related prospectus of any document incorporated or deemed to be
incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, related prospectus or documents so that, in the case of the
Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not
misleading, and that in the case of the related prospectus, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which they were
made, not misleading; and (v) the Company’s reasonable determination that a post-effective amendment to the Registration Statement would be appropriate; and the Company will promptly make
available to the Investor any such supplement or amendment to the related prospectus. The Company shall not deliver to the Investor any Advance Notice during the continuation of any of the
foregoing events.

Section 6.07

Consolidation; Merger. The Company shall not, at any time after
the date hereof, effect any merger or consolidation of the Company with or into another Person, or transfer all or substantially all the assets of the Company to another Person (each, a “
Consolidation Event”) unless the Person

 

surviving such merger or consolidation (if not the Company) or such acquiring entity assumes by written instrument the obligations of the
Company under this Agreement.

Section 6.08

Issuance of the Company’s Common Stock. The sale of
the Shares, to the extent not covered by the Registration Statement, shall be made in accordance with the provisions and requirements of Regulation D and any applicable state securities law.

Section 6.09

Review of Public Disclosures. All SEC filings (including,
without limitation, all filings required under the Exchange Act, which include Forms 10-Q and 10-K and 8-K, etc) and other public disclosures made by the Company, including, without limitation, all
press releases, investor relations materials, and scripts of analysts meetings and calls, shall be reviewed and approved for release by the Company’s Chief Executive Officer and, if containing
financial information, the Company’s independent certified public accountants. 

Section 6.10

Market Activities.

The Company will not, directly or indirectly, (i) take any action designed to
cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of the Common Stock or (ii) sell, bid for or purchase the Common Stock during the Commitment Period, or (iii) pay anyone any compensation for soliciting purchases of the Common Stock.

Section 6.11

Opinion of Counsel Concerning Resales. Provided that the
Investor’s resale of Common Stock received pursuant to this Agreement may be freely sold by the Investor either pursuant to an effective Registration Statement or in accordance with Rule 144,
the Company shall obtain for the Investor, at the Company’s expense, any and all opinions of counsel which may be required by the Company’s transfer agent to issue such shares free of
restrictive legends, or to remove legends from such shares. 

Section 6.12

Subsequent Officer/Director Registration Statements. Commencing
on the Execution Date and expiring upon termination of this Agreement, the Company agrees that it will not, without the prior written consent of Investor, register for resale any shares of the common
stock of the Company belonging to any Officer or Director of the Company.  

Article VII.

Conditions for Advance and Conditions to Closing

Section 7.01

Conditions Precedent to the Right of the Company to Deliver an Advance Notice
. The right of the Company to deliver an Advance Notice is subject to the fulfillment by the Company, on such relevant Advance Notice Date, of each of the following conditions:

(a)

Accuracy of the Company’s Representations and Warranties.
 The representations and warranties of the Company shall be true and correct in all material respects (except for representations and warranties that speak as of a specific date).

(b)

Registration of the Common Stock with the SEC. There is an
effective Registration Statement pursuant to which the Investor is permitted to utilize the prospectus thereunder to resell all of the shares of Common Stock issuable pursuant to such Advance Notice,
and the Company believes, in good faith, that such effectiveness will continue uninterrupted for the foreseeable future. Neither the Company nor the Investor shall have received notice that the
SEC has issued or intends to issue a stop order with respect to the Registration Statement or that the SEC otherwise has suspended or withdrawn

 

the effectiveness of the Registration Statement, either
temporarily or permanently, or intends or has threatened to do so (unless the SEC’s concerns have been addressed and the Investor is reasonably satisfied that the SEC no longer is considering or
intends to take such action), and (ii) no other suspension of the use or withdrawal of the effectiveness of the Registration Statement or related prospectus shall exist.

(c)

Authority. The Company shall have obtained all permits and
qualifications required by any applicable state in accordance with the Registration Rights Agreement for the offer and sale of the shares of Common Stock, or shall have the availability of exemptions
therefrom. The sale and issuance of the shares of Common Stock shall be legally permitted by all laws and regulations to which the Company is subject.

(d)

Fundamental Changes. There shall not exist any fundamental changes
to the information set forth in the Registration Statement which would require the Company to file a post-effective amendment to the Registration Statement. 

(e)

Performance by the Company. The Company shall have
performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement and the Registration Rights Agreement to be performed, satisfied or
complied with by the Company at or prior to each Advance Notice Date.

(f)

No Injunction. No statute, rule, regulation, executive
order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits or directly and adversely
affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have a Material Adverse Effect.

(g)

No Suspension of Trading in or Delisting of Common Stock.
 The Common Stock is trading or is quoted on a Principal Market and all of the Shares issuable pursuant to such Advance Notice will be listed or quoted for trading on such Principal Market (and
the Company believes, in good faith, that the trading or quoting of the Common Stock on a Principal Market will continue uninterrupted for the foreseeable future. The issuance of Shares with
respect to the applicable Advance Notice will not violate the shareholder approval requirements of the Principal Market. The Company shall not have received any notice threatening the continued
listing or quotation of the Common Stock on the Principal Market.

(h)

Maximum Advance Amount. The amount of an Advance requested
by the Company shall not exceed the Maximum Advance Amount.

(i)

Authorized. There shall be a sufficient number of authorized
but unissued and otherwise unreserved shares of Common Stock available for the issuance of all of the Shares. 

(j)

Executed Advance Notice. The Investor shall have received
the Advance Notice executed by an officer of the Company and the representations contained in such Advance Notice shall be true and correct as of each Advance Notice Date.

(k)

Continuing DWAC Eligibility. The Common Stock to be issued
pursuant to the Advance shall continue to be eligible for electronic transmission to and from the Company’s transfer agent through the Deposit/Withdrawal at Custodian system maintained by the
Depository Trust Company. 

(l)

Continuing Clearing House Acceptability. The Common Stock to
be issued pursuant to the Advance shall continue to be eligible for deposit with and clearing through the Depository Trust Company or another FINRA member clearing firm without cost or expense to the
investor.

Article VIII. 

Due Diligence Review; Non-Disclosure of Non-Public Information

Section 8.01

Non-Disclosure of Non-Public Information.

(a)

The Company covenants and agrees that it shall refrain from disclosing, and
shall cause its officers, directors, employees and agents to refrain from disclosing, any material non-public information to the Investor without also disseminating such information to the public,
unless prior to disclosure of such information the Company identifies such information as being material non-public information and provides the Investor with the opportunity to accept or refuse to
accept such material non-public information for review.

(b)

Nothing herein shall require the Company to disclose non-public information to
the Investor or its advisors or representatives, and the Company represents that it does not disseminate non-public information to any investors who purchase stock in the Company in a public
offering, to money managers or to securities analysts, provided, however, that notwithstanding anything herein to the contrary, the Company will, as hereinabove provided, immediately notify the
advisors and representatives of the Investor and, if any, underwriters, of any event or the existence of any circumstance (without any obligation to disclose the specific event or circumstance) of
which it becomes aware, constituting non-public information (whether or not requested of the Company specifically or generally during the course of due diligence by such persons or entities), which,
if not disclosed in the prospectus included in the Registration Statement would cause such prospectus to include a material misstatement or to omit a material fact required to be stated therein in
order to make the statements, therein, in light of the circumstances in which they were made, not misleading. Nothing contained in this Section 8.01 shall be construed to mean that Persons or
entities other than the Investor (without the written consent of the Investor prior to disclosure of such information) may not obtain non-public information in the course of conducting due diligence
in accordance with the terms of this Agreement and nothing herein shall prevent any such Persons or entities from notifying the Company of their opinion that based on such due diligence by such
Persons or entities, that the Registration Statement contains an untrue statement of material fact or omits a material fact required to be stated in the Registration Statement or necessary to make
the statements contained therein, in light of the circumstances in which they were
made, not misleading.

Article IX. 

Choice of Law/Jurisdiction

This Agreement shall be governed by and interpreted in accordance with the laws of
the State of New York without regard to the principles of conflict of laws. The parties further agree that any action between them shall be heard in New York County, New York, and expressly
consent to the jurisdiction and venue of the Supreme Court of New York, sitting in New York County, New York and the United States District Court for the Southern District of New York, sitting in
Manhattan, New York, for the adjudication of any civil action asserted pursuant to this Agreement.

Article X. Assignment; Termination

Section 10.01

Assignment. Neither this Agreement nor any rights of the
Company hereunder may be assigned to any other Person. 

Section 10.02

Termination. 

(a)

Unless earlier terminated as provided hereunder, this Agreement shall terminate
automatically on the earliest of (i) the first day of the month next following the second (2nd) anniversary of the Effective Date, or (ii) the date on which the Investor shall have
made payment of Advances pursuant to this Agreement in the aggregate amount of the Commitment Amount. 

(b)

The Company may terminate this Agreement effective upon fifteen Trading
Days’ prior written notice to the Investor; provided that (i) there are no Advances outstanding for which a Closing has not occurred, and (ii) the Company has paid all amounts owed to the
Investor pursuant to this Agreement. This Agreement may be terminated at any time by the mutual written consent of the parties, effective as of the date of such mutual written consent unless
otherwise provided in such mutual written consent. In the event of any termination of this Agreement by the Company hereunder, so long as the Investor owns any Shares and at the time of any
such termination the Investor will promptly inform the Company in writing of such ownership and thereafter when it has sold all such Shares, unless all of such Shares may be resold by the Investor
without registration and without any time, volume or manner limitations pursuant to Rule 144, the Company shall not suspend (except as provided for in the Registration Rights Agreement) or
withdraw the Registration Statement or otherwise cause the Registration Statement to become ineffective, or voluntarily delist the Common Stock from, the Principal Market without listing the Common
Stock on another Principal Market. 

(c)

The obligation of the Investor to make an Advance to the Company pursuant to
this Agreement shall terminate permanently (including with respect to an Advance Date that has not yet occurred) in the event that (i) there shall occur, for any reason other than due to the acts of
the Investor, any stop order or suspension of the effectiveness of the Registration Statement for an aggregate of fifty (50) Trading Days during the Commitment Period, or (ii) the Company shall at
any time fail materially to comply with the requirements of Article VI of this Agreement and such failure is not cured within 30 days after receipt of written notice from the Investor; provided,
however, that this termination provision shall not apply to any period commencing upon the filing of a post-effective amendment to such Registration Statement and ending upon the date on which
such post effective amendment is declared effective by the SEC. 

(d)

Nothing in this Section 10.02 shall be deemed to release the Company or the
Investor from any liability for any breach under this Agreement, or to impair the rights of the Company or the Investor to compel specific performance by the other party of its obligations under this
Agreement.   

Article XI. Notices

Any notices, consents, waivers, or other communications required or permitted to be
given under the terms of this Agreement must be in writing and will be deemed to have been delivered (i) upon receipt, when delivered personally; (ii) if it is a notice that is not related to an
Advance, upon receipt, when sent by facsimile, provided a copy is mailed by U.S. certified mail, return receipt requested; (iii) if it is a notice related to an Advance, upon receipt, when sent by
facsimile, provided (a) the recipient of such notice acknowledges the receipt of such notice, or (b) a copy is mailed by U.S. first class mail; (iv) three (3) days after being sent by U.S. certified
mail, return receipt requested, or (v) one (1) day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The
addresses and facsimile numbers for such communications shall be:

		
	If to the Company, to:

	Bioheart, Inc.

	 
	13794 NW 4th Street, Suite 212

	 
	Sunrise, Florida 33325

	 
	Attention: 

Chief Executive Officer

	 
	Telephone:

(954) 835-1500

	 
	Facsimile:

(954) 845-9976

Email:  csguck@bioheart.com

	 
	 

	With a copy to:

	Sichenzia Ross Friedman Ference LLP

	 
	Att: Gregory Sichenzia

61 Broadway, 32nd Floor

	 
	New York, NY 10006

	 
	Telephone:

(212) 930-9700

	 
	Facsimile:

(212) 930-9725

	 
	 

	If to the Investor(s):

	Greystone Capital Partners

	 
	1170 Kane Concourse, Suite 404

Bay Harbor, FL 33154

Attention:

Bryan Collins, President

	 
	Telephone:

954-536-6491

	 
	Facsimile:

305-396-2000

Email: brc279@gmail.com

	 
	 

Each party shall provide five (5) days prior written notice to the other party of any change in address or
facsimile number.

Article XII. Miscellaneous

Section 12.01

Counterparts. This Agreement may be executed in two or more
identical counterparts, all of which shall be considered one and the same agreement and shall become effective as of the Execution Date when counterparts have been signed by each party and delivered
to the other party. In the event any signature page is delivered by facsimile transmission, the party using such means of delivery shall cause four (4) additional originally executed signature
pages to be physically delivered to the other party within five (5) days of such delivery by facsimile transmission, though failure to deliver such copies shall not affect the validity of this
Agreement.

Section 12.02

Entire Agreement; Amendments. This Agreement supersedes all
other prior oral or written agreements between the Investor, the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the
instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither
the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an
instrument in writing signed by the party to be charged with enforcement.

Section 12.03

Reporting Entity for the Common Stock. The reporting entity
relied upon for the determination of the trading price, trading volume and the VWAP of the Common Stock on any given Trading Day for the purposes of this Agreement shall be Bloomberg, L.P. or any
successor thereto. The written mutual consent of the Investor and the Company shall be required to employ any other reporting entity.

Section 12.04

Fees and Expenses. Each of the parties shall pay its own fees
and expenses (including the fees of any attorneys, accountants, appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby. 

Section 12.05

Brokerage. Each of the parties hereto represents that it has
had no dealings in connection with this transaction with any finder or broker who will demand payment of any fee or commission from the other party. The Company on the one hand, and the
Investor, on the other hand, agree to indemnify the other against and hold the other harmless from any and all liabilities to any Person claiming brokerage commissions or finder’s fees on
account of services purported to have been rendered on behalf of the indemnifying party in connection with this Agreement or the transactions contemplated hereby.

Section 12.06

Confidentiality. If for any reason the transactions
contemplated by this Agreement are not consummated, each party hereto shall keep confidential any information obtained from the other party (except information publicly available or in such
party’s domain prior to the date hereof, and except as required by court order) and shall promptly return to the other party all schedules, documents, instruments, work papers or other written
information without retaining copies thereof, previously furnished to it as a result of this Agreement or in connection herein.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the parties hereto have caused this Standby Equity Distribution Agreement to be executed
by the undersigned, thereunto duly authorized, as of the date first set forth above.

		
	 
	COMPANY:

	 
	BIOHEART, INC.

	 
	 

	 
	By: /s/Mike Tomas

	 
	Mike Tomas

	 
	President and Chief Executive Officer

	 
	 

	 
	 

	 
	INVESTOR:

	 
	GREYSTONE CAPITAL PARTNERS

	 
	 

	 
	 

	 
	 

	 
	 

	 
	By: /s/Bryan Collins

	 
	Name:

Bryan Collins

	 
	Title:

President

	 
	 

EXHIBIT A

ADVANCE NOTICE

BIOHEART, INC.

The undersigned, _______________________ hereby certifies, with respect to the offer and sale of shares of Common
Stock of BIOHEART, INC. (the “Company”) issuable in connection with this Advance Notice, delivered pursuant to the Standby Equity Distribution Agreement (the “
Agreement”), as follows: 

1.

The undersigned is the duly elected ______________ of the Company.

2.

There are no fundamental changes to the information set forth in the Registration Statement which
would require the Company to file a post effective amendment to the Registration Statement. 

3. 

The Company has performed in all material respects all covenants and agreements to be performed
by the Company and has complied in all material respects with all obligations and conditions contained in the Agreement on or prior to the Advance Notice Date, and shall continue to perform in all
material respects all covenants and agreements to be performed by the Company through the applicable Advance Date and Closing. All conditions to the delivery of this Advance Notice required to
be satisfied by the Company are satisfied as of the date hereof.

4.

The undersigned hereby represents, warrants and covenants that the Company has made all filings
(“SEC Filings”) required to be made by it pursuant to applicable securities laws (including, without limitation, all filings required under the Securities Exchange Act of 1934, which
include Forms 10-Q or 10-K or 8-K, etc.). All SEC Filings and other public disclosures made by the Company, including, without limitation, all press releases, analysts meetings and calls, etc.
(collectively, the “Public Disclosures”), have been reviewed and approved for release by the Company’s Chief Executive Officer and, if containing financial information, the
Company’s independent certified public accountants. None of the Company’s Public Disclosures contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

5.

The Advance requested is _____________________.

The undersigned has executed this Advance Notice this _ day of _________________.

BIOHEART, INC.

By:

Name:

Title:

If Returning This Advance Notice via Facsimile Please Send To: 305-396-2000

If by Mail, via Federal Express To: 

Greystone Capital Partners

1170 Kane Concourse, Suite 404

Bay Harbor, FL 33154

Attention: Bryan Collins, President

If by email, to:

brc279@gmail.com

EXHIBIT B

Capitalization Table

			
	 
	 
	
 As of 

	 
	 
	
October 31, 2011

	Shares of Preferred Stock Issued & Outstanding

	 
	0

	Shares of Common Stock Issued & Outstanding

	 
	81,791,338

	 
	 
	 

	Outstanding Warrants @

	 $         0.03 

	1,935,490

	Outstanding Warrants @

	 $         0.05 

	1,475,000

	Outstanding Warrants @

	 $         0.06 

	3,400,020

	Outstanding Warrants @

	 $         0.08 

	1,953,235

	Outstanding Warrants @

	 $         0.09 

	55,560

	Outstanding Warrants @

	 $         0.10 

	500,000

	Outstanding Warrants @

	 $         0.11 

	454,550

	Outstanding Warrants @

	 $         0.13 

	636,365

	Outstanding Warrants @

	 $         0.14 

	209,508

	Outstanding Warrants @

	 $         0.15 

	364,302

	Outstanding Warrants @

	 $         0.18 

	3,986,705

	Outstanding Warrants @

	 $         0.19 

	1,689,375

	Outstanding Warrants @

	 $         0.20 

	58,910

	Outstanding Warrants @

	 $         0.22 

	51,390

	Outstanding Warrants @

	 $         0.23 

	62,635

	Outstanding Warrants @

	 $         0.25 

	35,715

	Outstanding Warrants @

	 $         0.53 

	1,766,585

	Outstanding Warrants @

	 $         0.54 

	56,670

	Outstanding Warrants @

	 $         0.55 

	24,000

	Outstanding Warrants @

	 $         0.58 

	28,128

	Outstanding Warrants @

	 $         0.59 

	183,672

	Outstanding Warrants @

	 $         0.61 

	24,000

	Outstanding Warrants @

	 $         0.64 

	190,002

	Outstanding Warrants @

	 $         0.65 

	538,035

	Outstanding Warrants @

	 $         0.66 

	909,090

	Outstanding Warrants @

	 $         0.68 

	79,896

	Outstanding Warrants @

	 $         0.70 

	36,435

	Outstanding Warrants @

	 $         0.71 

	848,665

	Outstanding Warrants @

	 $         0.73 

	118,400

	Outstanding Warrants @

	 $         0.74 

	76,692

	Outstanding Warrants @

	 $         0.77 

	14,061

	Outstanding Warrants @

	 $         0.78 

	84,966

	Outstanding Warrants @

	 $         0.79 

	972,318

	Outstanding Warrants @

	 $         0.80 

	153,327

	Outstanding Warrants @

	 $         0.82 

	60,882

	Outstanding Warrants @

	 $         0.84 

	25,716

	Outstanding Warrants @

	 $         0.85 

	63,804

	Outstanding Warrants @

	 $         0.86 

	20,832

	Outstanding Warrants @

	 $         0.89 

	12,972

			
	Outstanding Warrants @

	 $         0.90 

	18,801

	Outstanding Warrants @

	 $         0.95 

	36,078

	Outstanding Warrants @

	 $         1.09 

	5,000

	Outstanding Warrants @

	 $         1.24 

	14,562

	Outstanding Warrants @

	 $         1.25 

	3,542

	Outstanding Warrants @

	 $         1.60 

	24,810

	Outstanding Warrants @

	 $         1.62 

	34,422

	Outstanding Warrants @

	 $         1.81 

	13,433

	Outstanding Warrants @

	 $         1.90 

	12,343

	Outstanding Warrants @

	 $         1.93 

	25,633

	Outstanding Warrants @

	 $         1.94 

	9,300

	Outstanding Warrants @

	 $         1.97 

	61,562

	Outstanding Warrants @

	 $         1.99 

	3,675

	Outstanding Warrants @

	 $         2.05 

	263,157

	Outstanding Warrants @

	 $         2.60 

	38,016

	Outstanding Warrants @

	 $         3.60 

	5,000

	Outstanding Warrants @

	 $         4.93 

	100,000

	Outstanding Warrants @

	 $         5.67 

	192,834

	Outstanding Warrants @

	 $         6.00 

	40,000

	Outstanding Warrants @

	 $         6.56 

	77,000

	Outstanding Warrants @

	 $         7.69 

	2,508,448

	 
	 Total 

	26,645,524

	 
	 
	 

	Outstanding Stock Options @

	 $         0.07 

	1,310,000

	Outstanding Stock Options @

	 $         0.10 

	1,250,000

	Outstanding Stock Options @

	 $         0.21 

	210,000

	Outstanding Stock Options @

	 $         0.50 

	500,000

	Outstanding Stock Options @

	 $         0.68 

	224,360

	Outstanding Stock Options @

	 $         0.71 

	184,580

	Outstanding Stock Options @

	 $         0.74 

	20,200

	Outstanding Stock Options @

	 $         0.85 

	70,000

	Outstanding Stock Options @

	 $         0.92 

	50,000

	Outstanding Stock Options @

	 $         5.25 

	159,500

	Outstanding Stock Options @

	 $         5.67 

	636,504

	Outstanding Stock Options @

	 $         7.69 

	39,572

	Outstanding Stock Options @

	 $         8.47 

	6,796

	 
	 Total 

	4,661,512

	 
	 
	 

	Convertible Promissory Note dated 5/16/11

	 $ 34,750.00 

	 

	Convertible Promissory Note dated 9/28/11

	 $ 35,000.00 

	 

	Convertible Promissory Note dated 10/1/11

	 $ 24,585.00 

	 

	Convertible Promissory Note dated 11/1/11

	 $139,728.82 

	 

	 
	 
	 

	Total Convertible Debt

	 $234,063.82Converted by EDGARwiz

Exhibit 10.77

REGISTRATION RIGHTS AGREEMENT

REGISTRATION RIGHTS AGREEMENT (this “Agreement”),
dated as of November 2, 2011, is between GREYSTONE CAPITAL PARTNERS, a Nevada corporation (the “Investor”), and BIOHEART, INC., a corporation organized and
existing under the laws of the State of Florida (the “Company”).

WHEREAS:

A.

In connection with the Standby Equity Distribution Agreement by and between the
parties hereto of even date herewith (the “Standby Equity Distribution Agreement”), the Company has agreed, upon the terms and subject to the conditions of the Standby Equity
Distribution Agreement, to issue and sell to the Investor that number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), which can
be purchased pursuant to the terms of the Standby Equity Distribution Agreement for an aggregate purchase price of up to $3,000,000. Capitalized terms not defined herein shall have the meaning
ascribed to them in the Standby Equity Distribution Agreement.

B.

To induce the Investor to execute and deliver the Standby Equity Distribution
Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute
(collectively, the “Securities Act”), and applicable state securities laws.

NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investor hereby agree as follows:

1.

DEFINITIONS.

As used in this Agreement, the following terms shall have the following meanings:

a.

“Prospectus” means the prospectus included in a
Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance
upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities
covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be
incorporated by reference in such Prospectus.

b.

“Registration Statement” means the registration statement
required to be filed hereunder and any additional registration statements contemplated by Section 2 hereof, including (in each case) the Prospectus, amendments and supplements to such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such
registration statement.

c.

“Rule 415” means Rule 415 promulgated by the SEC pursuant
to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such
Rule.

2.

REGISTRATION.

a.

Filing of a Registration Statement. The Company shall prepare
and file with the SEC a Registration Statement, or multiple Registration Statements, on Form S-1 (or if the Company is then eligible, on Form S-3) for the resale by the Investor of the Registrable
Securities. The Company in its sole discretion may choose when to file such Registration Statements, provided, however, that pursuant to the Standby Equity Distribution Agreement the
Company shall not have the ability to make any Advances until the effectiveness of a Registration Statement. Each Registration Statement shall contain the “Plan of Distribution” section in substantially the form attached hereto as Exhibit A and contain all the required disclosures set forth on Exhibit B.

b.

Maintaining a Registration Statement. The Company shall use
its best efforts to cause any Registration Statement that has been declared effective to remain effective at all times until all Registrable Securities contained in such Registration Statement cease
to be Registrable Securities (the “Registration Period”). Each Registration Statement (including any amendments or supplements thereto and prospectuses contained
therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the
circumstances in which they were made, not misleading. 

c.

Filing Procedures. Prior to the filing of any Registration
Statement with the SEC, the Company shall furnish a draft of such Registration Statement to the Investor for its review and comment. The Investor shall furnish comments on a Registration
Statement to the Company within twenty four (24) hours of the receipt thereof. 

3.

RELATED OBLIGATIONS.

a.

The Company shall, not less than three (3) business days prior to the filing of a
Registration Statement and not less than one (1) business day prior to the filing of any related amendments and supplements to all Registration Statements (except for annual or quarterly reports on
Forms 10-K and 10-Q, respectively), furnish to the Investor copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by
reference) will be subject to the reasonable and prompt review of the Investor, but under no circumstances shall the Investor have more than twenty four (24) hours to review the documents. The
Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Investors shall reasonably object in good faith, provided that, the
Company is notified of such objection in writing no later than two (2) business days after the Investors have been so furnished copies of a Registration Statement.

b.

The Company shall (i) prepare and file with the SEC such
amendments (including post-effective amendments) and supplements to a Registration Statement and the Prospectus used in connection with such Registration Statement, which prospectus is to be
filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep such Registration Statement effective at all times during the Registration Period, and prepare and file
with the SEC such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus to be amended or
supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and as so supplemented or amended to be filed pursuant to Rule 424; (iii) respond as promptly as
reasonably possible to any comments received from the SEC with respect to a Registration Statement or any amendment thereto and as promptly as reasonably possible provide the Investors true and
complete copies of all correspondence from and to the SEC relating to a Registration Statement (provided that the Company may excise any information contained therein which would constitute material
non-public information as to any Investor which has not executed a confidentiality agreement with the Company); and (iv) comply with the provisions of the Securities Act with respect to the
disposition of all Registrable Securities of the Company covered by such Registration 

 

2 

 

Statement until such time as all of such Registrable Securities shall have been disposed of in accordance with
the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement. In the case of amendments and supplements to a Registration Statement which are
required to be filed pursuant to this Agreement (including pursuant to this Section 3(b)) by reason of the
Company’s filing a report on Form 10-K, Form 10-Q, or Form 8-K or any analogous report under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the
Company shall incorporate such report by reference into the Registration Statement, if applicable, or shall file such amendments or supplements with the SEC in a timely manner, but in any event no
longer than three (3) Business Days after the date on which the Exchange Act report is filed which created the requirement for the Company to amend or supplement the Registration Statement.

c.

The Company shall furnish to the Investor without charge, (i) at least one (1)
copy of such Registration Statement as declared effective by the SEC and any amendment(s) thereto, including financial statements and schedules, all documents incorporated therein by reference, all
exhibits and each preliminary prospectus, (ii) 10 copies of the final prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as
the Investor may reasonably request) and (iii) such other documents as the Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned
by the Investor.

d.

The Company shall use its best efforts to (i) register and qualify the Registrable
Securities covered by a Registration Statement under such other securities or “blue sky” laws of such jurisdictions in the United States as the Investor reasonably requests,
(ii) prepare and file in those jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the
effectiveness thereof during the Registration Period, (iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the
Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, that the Company shall
not be required in connection therewith or as a condition thereto to (w) make any change to its certificate of incorporation or by-laws, (x) qualify to do business in any jurisdiction where it would
not otherwise be required to qualify but for this Section 3(d), (y) subject itself to general taxation in any such jurisdiction, or (z) file a general consent to service of process in any such
jurisdiction. The Company shall promptly notify the Investor of the receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the
Registrable Securities for sale under the securities or “blue sky” laws of any jurisdiction in the United States or its receipt of actual notice of the initiation or threat of any
proceeding for such purpose.

e.

If, pursuant to Section 3(d) above, the Company becomes aware of an event or
development, the result of which causes the Prospectus included in the Registration Statement, as then in effect, to include an untrue statement of a material fact or omission, to state a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading (provided that in no event shall such notice
contain any material, nonpublic information), as promptly as practicable after becoming aware of such event or development, the Company shall notify the Investor in writing of the happening of such
event or development, and promptly prepare a supplement or amendment to such Registration Statement to correct such untrue statement or omission, and deliver 10 copies of such supplement or
amendment to the Investor. The Company shall also promptly notify the Investor in writing (i) when a prospectus or any prospectus supplement or post-effective amendment has been filed, and when
a Registration Statement or any post-effective amendment has become effective (notification of such effectiveness shall be delivered to the Investor by facsimile on the same day of such
effectiveness), and (ii) of any request by the SEC for amendments or supplements to a Registration Statement or related prospectus or related information.. 

 

3 

 

f.

The Company shall use its best efforts to prevent the issuance of any stop order
or other suspension of effectiveness of a Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction within the United States of
America and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify the Investor of the issuance of such order
and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding for such purpose.

g.

If, after the execution of this Agreement, the Investor believes, after
consultation with its legal counsel, that it could reasonably be deemed to be an underwriter of Registrable Securities, at the request of the Investor, the Company shall furnish to the Investor, on
the date of the effectiveness of the Registration Statement and thereafter from time to time on such dates as the Investor may reasonably request (i) a letter, dated such date, from the
Company’s independent certified public accountants in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering,
and (ii) an opinion, dated as of such date, of counsel representing the Company for purposes of such Registration Statement, in form, scope and substance as is customarily given in an underwritten
public offering, addressed to the Investor.

h.

If, after the execution of this Agreement, the Investor believes, after
consultation with its legal counsel, that it could reasonably be deemed to be an underwriter of Registrable Securities, at the request of the Investor, the Company shall make available for inspection
by (i) the Investor and (ii)  one firm of accountants or other agents retained by the Investor (collectively, the “Inspectors”) all pertinent financial and other records,
and pertinent corporate documents and properties of the Company (collectively, the “Records”), as shall be reasonably deemed necessary by each Inspector, and cause the
Company’s officers, directors and employees to supply all information which any Inspector may reasonably request; provided, however, that each Inspector shall agree, and the Investor hereby
agrees, to hold in strict confidence and shall not make any disclosure (except to an Investor) or use any Record or other information which the Company determines in good faith to be
confidential, and of which determination the Inspectors are so notified, unless (a) the disclosure of such Records is necessary to avoid or correct a misstatement or omission in any Registration
Statement or is otherwise required under the Securities Act, (b) the release of such Records is ordered pursuant to a final, non-appealable subpoena or order from a court or government body of
competent jurisdiction, or (c) the information in such Records has been made generally available to the public other than by disclosure in violation of this or any other agreement of which the
Inspector and the Investor has knowledge. The Investor agrees that it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of competent
jurisdiction or through other means, give prompt notice to the Company and allow the Company, at its expense,
to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, the Records deemed confidential.

i.

The Company shall hold in confidence and not make any disclosure of information
concerning the Investor provided to the Company unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is
necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other final, non-appealable order
from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this Agreement or any
other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning the Investor is sought in or by a court or governmental body of competent
jurisdiction or through other means, give prompt written notice to the Investor and allow the Investor, at the Investor’s expense, to undertake appropriate action to prevent disclosure of, or to
obtain a protective order for, such information.

 

4 

 

j.

The Company shall use its best efforts either to cause all the Registrable
Securities covered by a Registration Statement (i) to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the
listing of such Registrable Securities is then permitted under the rules of such exchange or to secure the inclusion for quotation on the OTC Bulletin Board for such Registrable Securities. The
Company shall pay all fees and expenses in connection with satisfying its obligation under this Section 3(j).

k.

The Company shall cooperate with the Investor, to the extent applicable, to
facilitate the timely preparation and delivery of certificates (not bearing any restrictive legend) representing the Registrable Securities to be offered pursuant to a Registration Statement and
enable such certificates to be in such denominations or amounts, as the case may be, as the Investor may reasonably request and registered in such names as the Investor may request.

l.

The Company shall use its best efforts to cause the Registrable Securities covered
by the applicable Registration Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable
Securities.

m.

The Company shall otherwise use its best efforts to comply with all applicable
rules and regulations of the SEC in connection with any registration hereunder.

n.

Within three (3) business days after a Registration Statement which covers
Registrable Securities is ordered effective by the SEC, the Company shall deliver, and shall cause legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities
(with copies to the Investor) confirmation that such Registration Statement has been declared effective by the SEC in the form attached hereto as Exhibit C.

o.

The Company shall take all other reasonable actions necessary to expedite and
facilitate disposition by the Investor of Registrable Securities pursuant to a Registration Statement.

4.

OBLIGATIONS OF THE INVESTOR.

a.

The Investor agrees that, upon receipt of any notice from the Company of the (i)
the happening of any event or development, following which the prospectus included in a Registration Statement, as then in effect, includes an untrue statement of a material fact or fails to state a
material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, or (ii) the issuance of any stop
order or other suspension of effectiveness of a Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction within the United
States of America, the Investor will immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement(s) covering such Registrable Securities until the
Investor’s receipt of written notice from the Company indicating that such event has been cured and confirming that re-sales may be made pursuant to such Registration Statement.
 Notwithstanding anything to the contrary, the Company shall cause its transfer agent to deliver unlegended certificates for shares of Common Stock to a transferee of the Investor in accordance
with the terms of the Standby Equity Distribution Agreement in connection with any sale of Registrable Securities with respect to which the Investor has entered into a contract for sale prior to the
Investor’s receipt of a notice from the Company described in this section and for which the Investor has not yet settled.

b.

The  Investor   covenants  and  agrees  that  it  will  comply  with  the
prospectus  delivery  requirements  of the  Securities  Act as applicable to it or an exemption  therefrom in connection  with sales of
Registrable Securities pursuant to the Registration Statement.

 

5 

 

5.

EXPENSES OF REGISTRATION.

All expenses incurred in connection with registrations, filings or qualifications pursuant to
Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees, printers, legal and accounting fees shall be paid by the Company. 

6.

INDEMNIFICATION.

With respect to Registrable Securities which are included in a Registration Statement under this
Agreement:

a.

To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold
harmless and defend the Investor, the directors, officers, partners, employees, agents, representatives of, and each Person, if any, who controls the Investor within the meaning of the Securities Act
or the Exchange Act (each, an “Indemnified Person”), against any losses, claims, damages, liabilities, judgments, fines, penalties, charges, costs, reasonable attorneys’ fees,
amounts paid in settlement or expenses, joint or several (collectively, “Claims”) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding,
investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an
indemnified party is or may be a party thereto (“Indemnified Damages”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced
or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment
thereto or in any filing made in connection with the qualification of the offering under the securities or other “blue sky” laws of any jurisdiction in which Registrable Securities are
offered (“Blue Sky Filing”), or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not
misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any final prospectus (as amended or supplemented, if the Company files any amendment thereof or
supplement thereto with the SEC) or the omission or alleged omission to state
therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading; or (iii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any state securities law, or any rule or regulation there under relating to the offer
or sale of the Registrable Securities pursuant to a Registration Statement (the matters in the foregoing clauses (i) through (iii) being, collectively, “Violations”). The
Company shall reimburse the Investor and each such controlling person promptly as such expenses are incurred and are due and payable, for any legal fees or disbursements or other reasonable expenses
incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section
6(a): (x) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the
Company by such Indemnified Person expressly for use in connection with the preparation of the Registration Statement or any such amendment thereof or supplement thereto; (y) shall not be available
to the extent such Claim is based on a failure of the Investor to deliver or to cause to be delivered the prospectus made available by the Company, if such prospectus was timely made available by the
Company pursuant to Section 3(e); and (z) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent
shall not be unreasonably withheld. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the
transfer of the Registrable Securities by the Investor.

 

6 

 

b.

In connection with a Registration Statement, the Investor agrees to indemnify, hold harmless and
defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors, each of its officers who signs the Registration Statement and each Person, if
any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each an “Indemnified Party”), against any Claim or Indemnified Damages to which any of
them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or is based upon any Violation, in each case to the extent,
and only to the extent, that such Violation occurs in reliance upon and in conformity with written information furnished to the Company by the Investor expressly for use in connection with such
Registration Statement; and, subject to Section 6(d), the Investor will reimburse any legal or other expenses reasonably incurred by them in connection with investigating or defending any such Claim;
provided, however, that the indemnity agreement contained in this Section 6(b) and the agreement with respect to contribution contained in Section 7 shall not apply to amounts paid in settlement of
any Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably withheld; provided, further, however, that the Investor shall be
liable under this Section 6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the sale of Registrable Securities pursuant to
such Registration Statement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer
of the Registrable Securities by the Investor. Notwithstanding
anything to the contrary contained herein, the indemnification agreement contained in this Section 6(b) with respect to any prospectus shall not inure to the benefit of any Indemnified Party if the
untrue statement or omission of material fact contained in the prospectus was corrected and such new prospectus was delivered to the Investor prior to the Investor’s use of the prospectus to
which the Claim relates.

c.

Promptly after receipt by an Indemnified Person or Indemnified Party under this Section 6 of
notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect
thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the
right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel
mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be; provided, however, that an Indemnified Person or Indemnified Party shall have
the right to retain its own counsel with the fees and expenses of not more than one counsel for such Indemnified Person or Indemnified Party to be paid by the indemnifying party, if, in the
reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate
due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or
Indemnified Person shall cooperate fully with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the
indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified
Party or Indemnified Person fully apprised at all times as to the status of the
defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written
consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the prior written consent of the
Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such Indemnified Party or Indemnified Person of a release from all liability in respect to such claim or litigation. Following indemnification as provided for
hereunder, the indemnifying party shall be subrogated to all rights of the 

 

7 

 

Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for
which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such
indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section 6, except to the extent that the indemnifying party is prejudiced in its ability to defend such
action.

d.

The indemnification required by this Section 6 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred.

e.

The indemnity agreements contained herein shall be in addition to (i) any cause of action or
similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law

f.

The
obligations
 of the parties under this Section 6 and the below Section 7 to indemnify or make contributions
to the payment and satisfaction of each of the Claims
shall survive the termination of this Agreement.

7.

CONTRIBUTION.

To the extent any indemnification by an indemnifying party is prohibited or limited by law, the
indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided,
however, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any
seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of
proceeds received by such seller from the sale of such Registrable Securities.

8.

REPORTS UNDER THE EXCHANGE ACT.

With a view to making available to the Investor the benefits of Rule 144 promulgated under the
Securities Act or any similar rule or regulation of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration (“Rule 144”) the Company agrees to:

a.

make and keep public information available, as those terms are understood and defined in Rule 144;

b.

file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act so long as the Company remains subject to such requirements (it being understood that nothing herein shall limit the Company’s obligations under Section
6.3 of the Standby Equity Distribution Agreement) and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and

c.

furnish to the Investor so long as the Investor owns Registrable Securities, promptly upon
request, (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, the Securities Act and the Exchange Act and (ii) any such other information as may be
reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration.

 

8 

 

9.

AMENDMENT OF REGISTRATION RIGHTS.

Provisions of this Agreement may be amended and the observance thereof may be waived (either
generally or in a particular instance and either retroactively or prospectively), only by a written agreement between the Company and the Investor. Any amendment or waiver effected in
accordance with this Section 9 shall be binding upon the Investor and the Company. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any
provision of any of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.

10.

MISCELLANEOUS.

a.

A Person is deemed to be a holder of Registrable Securities whenever such Person owns or is deemed
to own of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities,
the Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities.

b.

Any notices, consents, waivers or other communications required or permitted to be given under the
terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided
confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one business day after deposit with a nationally recognized overnight
delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall be:

		
	If to the Company, to:

	Bioheart, Inc.

	 
	13794 NW 4th Street, Suite 212

	 
	Sunrise, Florida 33325

	 
	Attention: 

Chief Executive Officer

	 
	Telephone:

(954) 835-1500

	 
	Facsimile:

954-845-9976

	 
	 

	 
	 

	With a copy to:

	Sichenzia Ross Friedman Ference Anslow LLP

	 
	Attention: Gregory Sichenzia

61 Broadway

	 
	New York, NY 10006

	 
	Telephone:

(212) 930-9700

	 
	Facsimile:

(212) 930-9725

	 
	 

 

9 

 

	If to the Investor, to:

	Greystone Capital Partners

	 
	1170 Kane Concourse, Suite 404

	 
	Bay Harbor, FL 33154

	 
	Attention:

Bryan Collins

	 
	Telephone:

954-536-6491

	 
	Facsimile:

305-396-2000

	 
	 

Any party may change its address by providing written notice to the other parties hereto at least five days prior to
the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated
by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by a courier or overnight courier
service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above,
respectively.

c.

Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay
by a party in exercising such right or remedy, shall not operate as a waiver thereof.

d.

The corporate laws of the State of New York shall govern all issues concerning the relative rights
of the Company and the Investor. All other questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State
of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws
of any jurisdiction other than the State of New York. Each party hereby irrevocably submits to the non-exclusive jurisdiction of the Supreme Court of the State of New York, sitting in New York
County, New York and the Federal District Court for the Southern District of New York sitting in Manhattan, New York, for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to
it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any
right to serve process in any manner permitted by law. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not
affect the validity or enforceability of the remainder of this
Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND
AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

e.

This Agreement shall inure to the benefit of and be binding upon the permitted successors and
assigns of each of the parties hereto.

f.

The headings in this Agreement are for convenience of reference only and shall not limit or
otherwise affect the meaning hereof.

g.

This Agreement may be executed in identical counterparts, each of which shall be deemed an
original but all of which shall constitute one and the same agreement. This Agreement, once 

 

10 

 

executed by a party, may be delivered to the other party hereto by facsimile transmission of a copy
of this Agreement bearing the signature of the party so delivering this Agreement.

h.

Each party shall do and perform, or cause to be done and performed, all such further acts and
things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the
purposes of this Agreement and the consummation of the transactions contemplated hereby.

i.

The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent and no rules of strict construction will be applied against any party.

j.

This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

11 

 

IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly
executed as of day and year first above written.

		
	 
	BIOHEART, INC.
 

	 
	 

	 
	By: /s/Mike Tomas

	 
	Name:

Mike Tomas

	 
	Title:

President & CEO

	 
	 

	 
	 

	 
	Greystone Capital Partners

	 
	 

	 
	 

	 
	By: /s/Bryan Collins

	 
	Name:

Bryan Collins

	 
	Title:   President 

	 
	 

 

12 

 

EXHIBIT A

PLAN OF DISTRIBUTION

Each Selling Stockholder (the “Selling Stockholders”) of the common stock and any
of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their shares of common stock on the __________ or any other stock exchange, market or trading
facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following
methods when selling shares:

·

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

·

block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction;

·

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

·

an exchange distribution in accordance with the rules of the applicable exchange;

·

privately negotiated transactions;

·

broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated
price per share;

·

through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; 

·

a combination of any such methods of sale; or

·

any other method permitted pursuant to applicable law.

The Selling Stockholders may also sell shares under Rule 144 under the Securities Act of 1933, as
amended (the “Securities Act”), if available, rather than under this prospectus.

Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to
participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with
NASD Rules 2440; and in the case of a principal transaction a markup or markdown in compliance with NASD Rules IM-2440. 

In connection with the sale of the common stock or interests therein, the Selling Stockholders may
enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Common Stock in the course of hedging the positions they assume.
 The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require
the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-

 

 

 

dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction).

The Selling Stockholders and any broker-dealers or agents that are involved in selling the shares
may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and
any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company
that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Common Stock. In no event shall any broker-dealer receive fees,
commissions and markups which, in the aggregate, would exceed eight percent (8%).

The Company is required to pay certain fees and expenses incurred by the Company incident to the
registration of the shares. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.
 

Because Selling Stockholders may be deemed to be “underwriters” within the meaning of the
Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder. In addition, any securities covered by this prospectus which
qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. There is no underwriter or coordinating broker acting in connection
with the proposed sale of the resale shares by the Selling Stockholders.

We agreed to keep this prospectus effective until the earlier of (i) the date on which the shares
may be resold by the Selling Stockholders without registration and without regard to any volume limitations by reason of Rule 144 under the Securities Act or any other rule of similar effect or (ii)
all of the shares have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale shares will be sold only through registered or
licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale shares may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

Under applicable rules and regulations under the Exchange Act, any person engaged in the
distribution of the resale shares may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to
the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including
Regulation M, which may limit the timing of purchases and sales of shares of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available
to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under
the Securities Act).

 

 

 

EXHIBIT B

OTHER DISCLOSURES 

See attachment provided separately. 

 

 

 

EXHIBIT C

FORM OF NOTICE OF EFFECTIVENESS

OF REGISTRATION STATEMENT

Attention:

Re:

BIOHEART, INC.

Ladies and Gentlemen:

We are counsel to Bioheart, Inc. (the “Company”), and have represented the Company
in connection with that certain Standby Equity Distribution Agreement (the “Standby Equity Distribution Agreement”) entered into by and between the Company and Greystone Capital
Partners (the “Investor”) pursuant to which the Company issued to the Investor shares of its Common Stock, par value $0.001 per share (the “Common Stock”).
 Pursuant to the Standby Equity Distribution Agreement, the Company also has entered into a Registration Rights Agreement with the Investor (the “Registration Rights Agreement”)
pursuant to which the Company agreed, among other things, to register the Registrable Securities (as defined in the Registration Rights Agreement) under the Securities Act of 1933, as amended (the
“Securities Act”). In connection with the Company’s obligations under the Registration Rights Agreement, on ____________ ____, the Company filed a Registration Statement
on Form ________ (File No. 333-_____________) (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) relating to the Registrable
Securities which names the Investor as a selling stockholder thereunder.

In connection with the foregoing, we advise you that a member of the SEC’s staff has advised
us by telephone that the SEC has entered an order declaring the Registration Statement effective under the Securities Act at [ENTER TIME OF EFFECTIVENESS] on [ENTER DATE OF EFFECTIVENESS]
 and we have no knowledge, after telephonic inquiry of a member of the SEC’s staff, that any stop order suspending its effectiveness has been issued or that any proceedings for that purpose
are pending before, or threatened by, the SEC and the Registrable Securities are available for resale under the Securities Act pursuant to the Registration Statement.

Very truly yours,

By: ____________________________

cc:

Greystone Capital Partners

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]